Summary: Catalent CEO John Chiminski to talks about the year ahead, offering projections for what 2021 holds in store for the biopharma industry.

Summary: Gwen Green, VP of Commercial Excellence at Catalent, and Endpoints News editors highlight the top 20 women in biopharma who have made it to the upper echelons of the drug development business in this on-demand webinar.

Summary: Karen Flynn, President of Biologics and Chief Commercial Officer, explains the challenges and opportunities changing how biomedical supply chains must plan and innovate to continue to serve patients and build resilient future options.

Summary: In a study published in Molecular Cancer Therapeutics, Catalent Biologics experts share the results of preclinical studies on their HER2-targeted ADC, CAT-01-106.

Summary: Hear Penelope Drake, Director of R&D for Catalent Biologics, present on the demonstrated success of SMARTag® across several therapeutic modalities in this on-demand webinar.

Summary: Hear from Mario Gargiulo, Catalent’s Region President, Biologics, Europe in this fireside chat interview with Dan Stanton, Editor and Founder, Bioprocess Insider.

Summary: In this executive summary, industry experts share case studies of how they’ve adapted to increasingly expedited regulatory reviews.

Summary: Bernie Clark, VP of Marketing and Strategy for Catalent Biologics, discusses the challenges and risks associated with this undertaking and the collaboration and innovation necessary to help combat coronavirus in this Q&A.

Summary: Catalent Biologics presents a case study on the investigational COVID-19 therapeutic candidate, lenzilumab, and its development from gene to late stage clinical trials.

Summary: Enzymes can be challenging to express and scale up to become biologic therapies.  In order to develop their optimized tissue plasmigen activator (tPA) to treat patients with hemorrhagic stroke...